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Due to shared routes of transmission, acute and chronic infec-
tion with hepatitis C virus is common among persons living
with HIV infection in many regions of the world. In the era
of effective antiretroviral therapy, acute HCV infection has been
increasingly recognized in HIV-infected persons, particularly
men who have sex with men, and liver disease, including
hepatocellular carcinoma, has emerged as a leading cause of
morbidity and mortality in those with chronic HCV infection,
particularly older adults with long-standing coinfection. Over
the past decade, the foundation for the management of acute
and chronic HCV infection has been interferon alfa. However,
due the high burden of treatment-related side effects and
low likelihood of sustained virologic response, the impact of
treatment with peginterferon/ribavirin on the burden of HCV
disease in has been limited. However, the anticipated availabil-
ity of safe, tolerable and highly efﬁcacious interferon-free, oral
HCV direct-acting antiviral combination therapies promise to
dramatically change the management of acute and chronic
HCV infection in HIV-infected persons. Preliminary data from
studies of such oral DAA regimens in HIV/HCV coinfected
patients suggest that coinfection with HIV will not impair
HCV cure with these regimens. Indeed, in the coming era of
high effective oral HCV DAA treatments, the only special
feature concerning treatment of acute and chronic HCV infec-
tion in HIV-infected patients may be drug interactions between
the antiretroviral drugs for HIV infection and direct-acting
antiviral drugs for HCV infection.
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Due to shared routes of transmission, acute and chronic coinfec-
tion with hepatitis C virus (HCV) is common among persons living
with HIV infection in many regions [1,2]. In the setting of effective
antiretroviral therapy, acute HCV infections have been increas-
ingly recognized among HIV-infected men who have sex with
men, leading to revised recommendations for HCV screening and
prevention among persons at risk for hepatitis C [3–7]. Further,
since the treatment of chronic HCV infection has historically been
substantially more difﬁcult than that of acute HCV infection, strat-
egies for the management of acutely infected patients with HIV
coinfection have been guided by the goal of preventing the
transition of acute to chronic infection [8–10]. However, 25% of
HIV-infected persons with acute hepatitis C will spontaneously
resolve their HCV infection during the initial months following
exposure, and emerging treatments for chronicHCV infectionwith
oral direct-acting antivirals (DAAs) promise to erase the historical
differential in HCV cure, following treatment in the acute and
chronic phase of infection [11,12]. With the removal of interferon,
themanagement of acute HCV infection in HIV-infected persons is
expected to change dramatically in the era of HCV DAAs [13].
Similarly, the management of HIV-infected patients with
chronic HCV infection can also be expected to change with the
advent of new therapies. In the era of effective antiretroviral ther-
apy, liver disease due to chronic HCV infection is a leading cause
of morbidity and mortality, particularly among older adults with
long-standing coinfection [14,15]. There is emerging evidence
that successful antiviral treatment of HIV infection and HCV
infection may reduce the risk of liver disease progression to cir-
rhosis and of its complications [1,16]. Suppression of HIV replica-
tion, leading to immune restoration and reduction in systematic
inﬂammation, may slow liver disease progression [17–22]. As
such, expert guidelines recommend antiretroviral therapy for
most HIV/HCV coinfected persons, regardless of CD4 cell count
[9,23,24]. Similarly, HCV treatment leading to HCV cure is
strongly associated with a reduced risk of serious liver disease,
including end-stage liver disease, hepatocellular carcinoma and
liver-related death [10,11]. For more than a decade, HCV treat-
ment with peginterferon/ribavirin has been recommended for
coinfected patients at risk for signiﬁcant hepatitis-related ﬁbrosis
[25–27]. However, on a population level, the effectiveness and
overall impact of interferon-based HCV therapy has been negligi-
ble due to low treatment uptake in many settings [28,29].14 vol. 61 j S108–S119
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This lack of effectiveness has been the result of the signiﬁcant
side effects associated with interferon and low HCV cure rates,
compared to persons without HIV coinfection [25,27,30–32].
The advent of oral HCV direct-acting antivirals has been accom-
panied by a sense of optimism regarding the treatment of HIV/
HCV coinfected HCV persons. Because these agents directly target
HCV non-structural proteins (NS3/4A protease, NS5B polymerase,
and NS5A protein) that have critical roles in the HCV life cycle,
oral combinations of such agents have minimized the negative
impact of host factors, such as race/ethnicity, IL28B genotype
and HIV coinfection on the likelihood of HCV cure. Indeed, preli-
minary data from clinical trials of HCV direct-acting antivirals in
combination with ribavirin or peginterferon/ribavirin or other
oral HCV DAAs have demonstrated similar HCV cure rates in
HIV-infected and HIV-uninfected persons, supporting the
hypothesis that coinfection with HIV will not impair HCV cure
with these regimens (Table 1) [33–39].
The purpose of this review is to address clinically relevant
topics related to the management of acute and chronic HCV infec-
tion in HIV-infected patients in the era of highly effective, oral
HCV direct-acting antiviral therapy.
Key Points
• Due to shared modes of transmission, acute and 
chronic infection with hepatitis C virus is common in 
persons with HIV infection
• In the era of effective antiretrovirals, the incidence 
of acute HCV infection has increased among HIV-
infected men who have sex with men, leading to 
recommendations for enhanced screening and 
prevention
• Morbidity and mortality due to prevalent chronic 
HCV infection among HIV-infected persons has also 
increased, leading to recommendations for more 
aggressive treatment of both HIV and HCV infections
• HCV treatment with regimens containing direct-acting 
antivirals has been very promising in HIV-infected 
persons, with high HCV cure rates observed. These 
novel HCV treatments are expected to transform the 
management of both acute and chronic HCV infection in 
this populationOverview of HCV direct-acting antivirals
Multiple oral direct-acting antiviral agents are currently
approved or being developed for the treatment of HCV infection
[40]. In contrast to interferon alfa, which targets type 1 interferon
receptors, found on many types of human cells, these drugs target
the virus directly, leading to the expectation that co-infection
with HIV will not impair their efﬁcacy [41]. HCV DAAs can be
classiﬁed according to their target in the HCV lifecycle: N3/4A
protease, NS5A, NS5B polymerase, NS4A, NS4B, P7, and viral
entry. While drug candidates have been identiﬁed for inhibition
of P7 (e.g., BIT225), NS4A (e.g., ACH-1095), NS4B (e.g., clemizole),
and viral entry (e.g., ITX-5061), the drug candidates/targets that
have advanced into clinical practice or late stage trials include:
inhibitors of NS3 protease, NS5A protein, and NS5B polymerase.Journal of Hepatology 2014Inhibitors of NS3 protease
This class of agents has the distinction of being the ﬁrst DAAs
approved for use in HCV infected patients, providing validation
of the in vitro models of anti-HCV activity. The initial approved
agents, boceprevir and telaprevir, are administered thrice daily
and have been characterized by potent antiviral activity against
genotype 1 and 2 with less activity against genotype 3 [42–44].
In addition, studies of telaprevir monotherapy or with peginter-
feron alone (no ribavirin) witnessed the rapid emergence of vari-
ants with decreased susceptibility to the protease inhibitor,
necessitating the co-administration of other HCV drugs, initially
peginterferon/ribavirin [45]. Following these initial agents, sime-
previr was approved in combination with peginterferon/ribavirin,
providing important advantages over the ﬁrst protease inhibitors.
Simeprevir is a potent inhibitor of the NS3 protease, administered
once daily and, unlike telaprevir and boceprevir, does not cause
anaemia [46,47]. Additional potent NS3 protease inhibitors,
administered once or twice daily (with or without ritonavir
boosting), are in late stage development, including: ABT450/
ritonavir, asunaprevir and MK-5172 [48,49]. These next genera-
tion drugs are being developed as part of interferon sparing com-
bination regimens with other oral HCV DAAs that target other
HCV non-structural proteins.
Inhibitors of NS5A protein
Since NS5A does not have enzymatic activity, the mechanism of
action of this class is incompletely understood; however, studies
indicate that these DAAs inhibit HCV replication as well as the
assembly and release of infectious virions [50]. Multiple NS5A
inhibitors are in late stage clinical development, including dacla-
tasvir, ledipasvir, ombitasvir, and MK-8742. The ﬁrst agent
reported in this class, daclatasvir, demonstrated rapid and pro-
found HCV RNA suppression after a single dose administered as
monotherapy [51]. Importantly, Lok and co-workers evaluated
the interferon-free combination of daclatasvir plus asunaprevir
(NS3 protease inhibitor) in patients with HCV genotype 1 who
had failed prior peginterferon/ribavirin therapy, providing the
ﬁrst evidence that chronic HCV infection could be eradicated
without interferon [52]. Subsequently, NS5A inhibitors have
emerged as critical components of several oral HCV DAA regi-
mens which have completed phase 3 clinical development and
are expected to be approved for clinical use [53–60].
Nucleosidic inhibitors of NS5B polymerase
This class of DAAs are nucleos(t)ide analogues that target the
highly conserved active site of the HCV polymerase and are incor-
porated by the polymerase into the HCV RNA intermediate, lead-
ing the chain termination. In vitro and in vivo, these agents have
been characterized by anti-viral activity against multiple HCV
genotypes and a high barrier to the selection of resistant variants
[61]. The ﬁrst agent in this class, approved for clinical use, was
sofosbuvir; this DAA is administered once daily, has few side
effects and has been highly effective in combination with ribavi-
rin or peginterferon/ribavirin or NS5A inhibitors (daclatasvir,
ledipasvir) or NS3 protease inhibitors (simeprevir) [62–64]. The
combination of sofosbuvir and ledipasvir has been coformulated
as a single, oral ﬁxed-dose combination tablet; in three phase 3
clinical trials (ION-1, ION-2, ION-3). 8 or 12 weeks of thisvol. 61 j S108–S119 S109
Table 1. Completed or ongoing clinical trials for HCV direct-acting antiviral regimens for a previously untreated HCV genotype 1 infection in HIV-infected adults.
Direct-acting antiviral agent
(Oral)
PegIFN (injection) Ribavirin 
(oral)
Treatment Sustained virologic 
response (%)
Telaprevir 750 mg every 8 h [34] Alfa-2a 180 µg/wk 1000 or 1200 mg/d 48 wk 
(telaprevir for the initial 12 wk only)
74 
Boceprevir 800 mg every 8 h 
[33]
Alfa-2b 1.5 µg/kg 
per wk 
600-1400 mg/d 48 wk 
(48 wk for PegIFN and ribavirin; 44 
wk for boceprevir)
63 
Simeprevir 150 mg once daily 
[39] 
Alfa-2a 180 µg/wk 1000 or 1200 mg/d 24 or 48 wk 
(simeprevir  for the initial 12 wk 
only)
79
Sofosbuvir 400 mg once daily 
[38] 
Alfa-2a 180 µg/wk 1000 or 1200 mg/d 12 wk 
(all drugs)
89
Sofosbuvir 400 mg once daily 
[35] 
None 1000 or 1200 mg/d 24 wk 
(all drugs)
76
Fixed-dose combination of 
sofosbuvir/ledipasvir (400/90 
mg) one tablet daily
None None 12 wk Pending
NCT01878799
Sofosbuvir 400 mg/d plus 
daclatasvir 30 or 60 or 90 mg 
once daily
None None 8 or 12 wk Pending
NCT02032888
Fixed-dose combination of 
ABT-450/ritonavir/ombitasvir 
(150/100/25 mg) once daily plus 
dasabuvir 250 mg twice daily
None 1000 or 1200 mg/d 12 or 24 wk Pending 
NCT01939197
Fixed dose combination
MK-5172/MK-8742 (100/50 mg) 
one tablet once daily 
None None 12 wk Pending 
NCT02105662
PegIFN, peginterferon; d, days; wk, weeks, h, hours.
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patients with HCV genotype 1 infection [53–55].
Non-nucleosidic inhibitors of NS5B polymerase
In contrast to nucleos(t)ide inhibitors, non-nucleoside inhibitors
bind to one of 4 allosteric sites (Thumb II and II; Palm I and II)
within NS5B, leading to inhibition of the enzyme [65]. This DAA
class has been characterized by moderate antiviral activity, which
is genotype/subtype speciﬁc and has been associated with the
rapid selection of resistant variants with monotherapy. These
DAAs have emerged as important components of several inter-
feron-free, oral HCV regimens, including dasabuvir that has been
developed in combination with ABT450/ritonavir/ombitasvir, and
beclabuvir (BMS-791325) that has been developed in combina-
tion with asunaprevir/daclatasvir [58,66–68].Acute hepatitis C virus infection
Epidemiology
The most efﬁcient route of HCV transmission is parenteral via
contaminated blood or blood products. Among persons who
inject drugs, coinfection may have been acquired via drug injec-
tion by syringe or other injection paraphernalia (i.e., ‘‘cookers,’’
ﬁlters, or water) previously used by an infected person [69].
Although less efﬁcient, HCV also can be transmitted sexually,
especially between HIV-infected men who have sex with menS110 Journal of Hepatology 2014(MSM). Over the past decade, acute HCV infections have increas-
ingly been recognized among MSM in urban regions of Europe,
Australia and the United States [3]. For example, in a study of
twelve European HIV cohorts that included more than three
thousand HIV-infected MSMs, the incidence of HCV seroconver-
sion increased from 1990 (0.9–2.2 cases/1000 person years) to
2007 (23.4–51.1 cases/1000 person-years) with the greatest rise
occurring after the advent of antiretroviral therapy [5]. Sexual
acquisition of HCV infection has been associated with high-risk
sexual behaviour (including unprotected anal intercourse and
ﬁsting) and non-injection drug use. In addition, the practice of
serosorting or identifying sex partners according to HIV status
has been linked to higher rates of high-risk behaviour among
HIV-infected seroconcordant partners, leading to transmission
of other sexually transmitted infections including HCV [2,6,70–
72]. In addition, sexual transmission of HCV may also be facili-
tated by the effect of HIV on hepatitis C viraemia (higher viral
load) and the presence of mucosal alterations by other sexually
transmitted pathogens (e.g., herpes simplex or syphilis).
The increased recognition of acute HCV infection has
prompted revisions to recommendations for screening, including
annual HCV antibody testing in HIV-infected persons who are
seronegative for HCV and monitoring of serum alanine amino-
transferase (ALT) levels every three to six months [9,73]. In addi-
tion, HCV-seronegative patients must be counselled regarding the
risk of sexual HCV acquisition and, although the effectiveness of
male condoms in reducing HCV transmission is not known, bar-
rier precautions are strongly recommended to reduce the risk
of sexually transmitted diseases, including HCV.vol. 61 j S108–S119
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Management of acute HCV infection
In 2011, the European AIDS Treatment Network (NEAT) Acute
Hepatitis C Infection Consensus Panel published recommenda-
tions regarding the detection and management of patients with
acute HCV infection [8]. The most strongly endorsed deﬁnitions
of acute HCV infection were a positive HCV antibody (seroconver-
sion) or a negative HCV antibody with detectable HCV RNA with
documentation of a negative HCV antibody in the previous
12 months. Alternative deﬁnitions for persons for whom histori-
cal HCV antibody testing is not available include detectable HCV
RNA and an acute rise is serum ALT levels coupled with exclusion
of other causes of hepatitis.
Following the identiﬁcation of acute HCV infection, strategies
for management have been based on the likelihood of spontane-
ous HCV clearance. In general, HIV coinfection has been associ-
ated with lower HCV clearance following acute infection. In
one, largely African-American cohort in Baltimore, Maryland,
HCV clearance was observed in 7% and 14% of patients with
and without HIV coinfection, respectively [74]. On the other
hand, in the EuroSIDA cohort, HCV RNA was not detected in
23% of nearly two thousand HCV seropositive, HIV-infected
patients [75]. More recently, these variable rates of HCV clear-
ance have been explained, in part, by the identiﬁcation of single
a nucleotide polymorphism (SNP) on chromosome 19 upstream
of the gene for IL28B (rs12979860) that is strongly associated
with spontaneous HCV clearance [11]. Interestingly, in the ﬁrst
study that demonstrated a relationship of the IL28B genotype
and spontaneous HCV clearance, Thomas and colleagues did not
observe a difference in the rate of HCV clearance in HIV-infected
and HIV-uninfected persons after accounting for the IL28B
genotype [11]. Among patients with the IL28B CC genotype, the
frequency of HCV clearance was similar in both HIV-infected
(52.2%) and HIV-uninfected patients (53.1%). However, the tem-
poral sequence of the acquisition of each infection may be an
important factor that is incompletely accounted for in studies
that rely on cross-sectional data. In many settings and in prior
studies, HCV infection was acquired and cleared or not cleared
prior to infection with HIV. Importantly, with the current epi-
demic of acute HCV infection in HIV-infected persons, the tempo-
ral sequence of infection is reversed (HIV ﬁrst, HCV second),
which has been associated with lower rates of spontaneous
HCV clearance [76]. Thus, in the era of effective antivirals and
the understanding of host determinants, the impact of HIV infec-
tion on the likelihood of spontaneous HCV clearance is uncertain
since earlier studies did not account for the IL28B genotype and
later studies are confounded by the HCV treatment during the
acute phase of infection.
However, following the identiﬁcation of the importance of the
IL28B polymorphism, several groups of investigators have devel-
oped clinical tools to predict the likelihood of spontaneous clear-
ance for individual patients. At the time of acute HCV diagnosis,
the presence of IL28B CC genotype, female sex and the presence
of jaundice are strongly associated with subsequent HCV clear-
ance [77,78]. In addition, signiﬁcant decline in serum HCV RNA
levels over the initial four weeks following HCV diagnosis has
been associated with higher likelihood of spontaneous clearance
[79]. Based on these observations, the NEAT panel recommended
that patients in whom the HCV RNA did not decline by at least
2 log10 or in whom HCV RNA was detected more than 12 weeks
after the diagnosis should be offered HCV treatment. On the otherJournal of Hepatology 2014hand, because of the high likelihood of HCV clearance with treat-
ment during the acute phase, a United States panel recom-
mended that HIV-infected patients with acute HCV infection
should be offered HCV treatment [9].
Both the European and United States panels recommend
treatment with peginterferon/ribavirin for 24 or 48 weeks with
shorter durations of therapy for patients who achieve rapid viro-
logic response (HCV RNA not detected after four weeks of treat-
ment. This recommendation was based on data, derived from
multiple, uncontrolled trials of peginterferon/ribavirin therapy,
HCV eradication was achieved in more than 75% of HIV-infected
patients with acute HCV infection, which was substantially
higher than the HCV cure rates achieved in HIV-infected patients
with chronic HCV infection, treated with the same regimen 
approximately 40% or less [10,80–82]. Thus, in the era of pegin-
terferon/ribavirin, the decision to initiate treatment for acute
HCV infection in HIV-infected persons represented the careful
consideration of the likelihood of spontaneous clearance and
the need to intervene with HCV treatment prior to the loss of
responsiveness to interferon alfa that is observed in the chronic
phase of HCV infection.
Role of HCV direct-acting antivirals for acute HCV infection
While there are very limited data on the use of HCV DAAs for the
treatment of acute HCV infection, Fierer and colleagues reported
HCV cure in 16 of 19 (84%) HIV-infected men, treated for acute
HCV genotype 1 infection with telaprevir (NS3 protease inhibitor)
plus peginterferon/ribavirin. Additional studies of HCV DAAs for
acute HCV infection are in development or underway. For exam-
ple, the Dutch Acute HCV in HIV Study (DAHHS) is underway to
assess the efﬁcacy of 12 weeks for boceprevir (NS3 protease inhib-
itor) plus peginterferon/ribavirin for the treatment of acute HCV
genotype 1 in HIV-infected patients (ClinicalTrials.gov Identiﬁer:
NCT01912495). In the United States, the SWIFT-C study is
currently underway to examine the safety and efﬁcacy of the
nucleotide analogue HCV NS5B polymerase inhibitor, sofosbuvir
plus ribavirin) for the treatment of HIV-infected persons
with acute HCV infection (ClinicalTrials.gov Identiﬁer:
NCT02128217). In Australia, the DAA-based Therapy for Recently
Acquired Hepatitis C II study (DARE C II) will also assess the com-
bination of sofosbuvir plus ribavirin for the treatment of acute
HCV infection (ClinicalTrials.gov Identiﬁer: NCT02156570).
In contrast to the limited data in the acute setting, large, phase
3 clinical trials of oral HCV DAAs for chronic HCV infection have
been completed, demonstrating excellent tolerability and safety,
as well as HCV cure rates in excess of 95%, following 12 weeks of
interferon-free therapy [53,60]. Further, traditional predictors of
poor response to peginterferon/ribavirin (e.g. race/ethnicity,
obesity, HCV RNA level, IL28B genotype, and HIV status) were
not associated with lower response to these oral, HCV DAA regi-
mens. Thus, as the treatment of chronic HCV infection shifts to
incorporate these oral HCV regimens, the management of
patients with acute HCV may also change since the primary rea-
son to rapidly start HCV treatment has been to prevent the tran-
sition from the acute phase to the chronic phase of infection,
which has been associated with poor interferon alfa response.
Although the optimal approach to the management of acute
HCV infection in HIV-infected persons will need to be determined
through clinical trials, cost-effectiveness analysis and expert
consensus, at least two strategies may be considered: (1) earlyvol. 61 j S108–S119 S111
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intervention with a short course (e.g., 4 weeks duration) of oral
HCV DAAs; or (2) delayed intervention (e.g., up to 24 weeks
following diagnosis) to allow for spontaneous HCV clearance, fol-
lowed by treatment of persons with persistent HCV infection
with oral HCV DAAs for the duration recommended for chronic
HCV infection. Regardless of strategy, all patients who clear acute
HCV infection with or without treatment must be educated
regarding the risk of reinfection, and measures should be imple-
mented to reduce the risk of reinfection [83]. In addition, these
HCV seropositive, HCV RNA negative patients should be moni-
tored with serum ALT and/or HCV RNA testing following sponta-
neous or treatment induced clearance [84].Chronic hepatitis C virus infection
Peginterferon/ribavirin
Based on multiple randomized controlled clinical trials, peginter-
feron/ribavirin is approved in many regions for the treatment of
chronic HCV infection [25–27,85]. Among patients who were
eligible for interferon-based treatment, the safety and tolerability
proﬁle of peginterferon/ribavirin has been similar in persons with
and without HIV coinfection. While drug interactions with anti-
retrovirals are uncommon, zidovudine is not recommended due
to additive bone marrow suppression, leading to worsening of
neutropenia and anaemia. Also, ribavirin increases exposure to
the active metabolite of didanosine which has caused clinical
toxicities, including pancreatitis, lactic acidosis, and peripheral
neuropathy; as such, its use is contraindicated [86]. In addition
to toxicity, the major limitation of peginterferon/ribavirin has
been the low rates of HCV cure in HIV-infected patients compared
to HIV-uninfected patients. For example, in the APRICOT and
RIBAVIC studies in HIV-coinfected patients, the sustained viro-
logic response (SVR) rates for genotype 1 were 29% and 20%,
respectively [25,85]. By comparison, in the study by Hadziyannis
and colleagues, HCVmonoinfected patients treated with the same
regimen as those in the APRICOT trial (ﬁxed-dose ribavirin,
800 mg/day) had higher sustained virologic response rates than
HIV coinfected patients (genotype 1, 41% >29% SVR) [87]. The poor
response in coinfected patients was most evident in those with
genotype 1 infection and high HCV RNA levels (>800,000 copies/
ml) in whom the SVR rate was only 18% compared to 36% for
similar patients without HIV coinfection. Since many HIV/HCV
coinfected patients with HIV/HCV coinfection have relatively high
HCV RNA levels and multiple relative or absolute contraindica-
tions to peginterferon/ribavirin, the effectiveness of this regimen
has been low in this population, leading to the characterization
of coinfected patients as ‘‘difﬁcult to treat’’ [28,88].
Direct-acting-antivirals for chronic HCV infection
By targeting the virus rather than the host, direct-acting antivirals
may improve both efﬁcacy and tolerability in HIV-infected
patients; indeed, in several clinical trials, DAAs have shown great
promise in this population. Multiple studies have demonstrated
high response rates with peginterferon/ribavirin plus a single
DAA, including HCV protease inhibitors (e.g., telaprevir, bocepre-
vir, simeprevir) and the nucleotide analogue polymerase inhibitor
sofosbuvir [35,36]. Further, data from studies of interferon-free,
oral DAA therapy have been reported with the observation of highS112 Journal of Hepatology 2014SVR rates and excellent tolerability. Taken together, these emerg-
ing data support the hypothesis that HIV coinfection does not
adversely impact the effectiveness of DAA therapy.
Boceprevir plus peginterferon/ribavirin
In treatment-naïve, HIV-uninfected patients with genotype 1
infection, following a 4 week lead-in phase of peginterferon/riba-
virin, boceprevir 800 mg every 8 h plus peginterferon/ribavirin
for 44 weeks achieved SVR in 68%; the SVR rate among
placebo-treated patients was 40% [43]. In a double-blind,
randomized phase 2 trial, the same regimen was evaluated in
treatment-naïve, HIV-infected patients with HCV genotype 1
coinfection. In this trial, 98 HIV/HCV-coinfected patients were
randomly assigned to receive the same regimen with a 4 week
lead-in phase, followed by 44 weeks of boceprevir (n = 64) or pla-
cebo (n = 34) [33]. On the basis of the initial drug interaction
studies in healthy volunteers, patients receiving efavirenz were
excluded; patients with undetected HIV RNA, taking ritonavir-
boosted HIV protease inhibitors (darunavir, atazanavir, and lopin-
avir) and the HIV integrase inhibitor, raltegravir, were enrolled.
However, after the study commenced, additional drug interaction
studies demonstrated potentially signiﬁcant bidirectional interac-
tions between HIV-1 protease inhibitors and boceprevir, leading
to recommendations against their co-administration [89]. The
majority of patients were male (65%–72%), white (81%–82%),
and infected with genotype 1a, (74%–80%). The median CD4 cell
count was relatively high (577–586 cells/mm3). Similar to the
ﬁndings in HIV-uninfected patients, the SVR rate was 62% in
the boceprevir-treated patients and 29% in the placebo-treated
patients. Although this study population was relatively small,
no difference in HCV response or HIV breakthrough was detected
among patients treated with ritonavir-boosted HIV protease
inhibitors and other antiretrovirals, despite the expectation of
lower drug concentrations, due the interaction between HIV
protease inhibitors and boceprevir. Similar to patients without
HIV coinfection, adverse events were more common among
patients who received boceprevir compared to those who
received placebo; patients taking boceprevir experienced more
anaemia, neutropenia, fever, anorexia, and gastrointestinal symp-
toms. Discontinuation of HCV treatment due to adverse events
was also more common in boceprevir-treated patients (20%)
compared with placebo-treated patients (9%).
In a second study, ANRS-HC27 BocepreVIH, 64 HIV-infected
patients with HCV genotype 1 who had failed to respond to prior
peginterferon/ribavirin therapy were treated with boceprevir
plus peginterferon/ribavirin. The total duration of HCV treatment
was either 48 or 72 weeks based on the HCV RNA response at
treatment week 8 [90]. Enrolled patients received either atazana-
vir/ritonavir (n = 32) or raltegravir (n = 27) with frequent HIV
RNA monitoring for patients taking atazanavir. The SVR rate
was 53% (34 of 64 patients), which was similar to the response
observed in a similar population of HIV uninfected patients
[91]. The safety and tolerability proﬁle was similar to the prior
studies; ten patients stopped therapy due to adverse events. No
HIV RNA breakthrough was observed.
Telaprevir plus peginterferon/ribavirin
In treatment-naïve, HCV genotype 1 infected patients without
HIV infection, telaprevir 750 mg every 8 h (12 weeks) forvol. 61 j S108–S119
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12 weeks in combination with peginterferon/ribavirin for 24 or
48 weeks achieved a SVR rate of 75%; the SVR rate among
placebo-treated patients was 45% [12]. In a double-blind, ran-
domized phase 2 trial, the same regimen was evaluated in treat-
ment-naïve, HIV-infected patients with genotype 1 coinfection
[34]. Patients were randomized to 12 weeks of peginterferon/
ribavirin plus telaprevir (n = 38) or placebo (n = 22), followed
by 36 weeks of peginterferon/ribavirin; all patients were treated
for 48 weeks (no response-guided therapy). On the basis of drug
interaction studies in healthy volunteers, enrolled patients
received either no antiretroviral therapy (n = 13) or atazanavir/
ritonavir (n = 23) or efavirenz (n = 24); patients receiving efavi-
renz were treated with higher telaprevir doses (1125 mg every
8 h) to offset the reduction in telaprevir levels by efavirenz. The
majority of patients were male (67%–100%), white (29%–87%),
and infected with genotype 1a (43%–80%). The median CD4 cell
count was high (514–675 cells/mm3). Similar to the ﬁndings in
HIV-uninfected patients, SVR was achieved in 74% of the telapre-
vir-treated patients compared with 45% in placebo-treated
patients. Adverse events were more frequently observed with
telaprevir. Speciﬁcally, telaprevir was associated with pruritus,
dizziness, headache nausea, rash, and anaemia. However, discon-
tinuation of HCV treatment study drugs because of adverse
events was uncommon (telaprevir, 3 patients). Further, no
adverse impact on HIV or its treatment with antiretroviral ther-
apy was detected.
In a second study, ANRS HC26 TelapreVIH, 69 HIV-infected
patients with genotype 1 coinfection who had failed prior pegin-
terferon/ribavirin therapy were treated with a 4 week lead-in of
peginterferon/ribavirin, followed by 12 weeks of telaprevir plus
peginterferon/ribavirin [92]. The total duration of HCV treatment
was either 48 or 72 weeks based on the HCV RNA response at
treatment week 8. Patients received HIV treatment that included
either atazanavir/ritonavir (n = 34), efavirenz (n = 13) or raltegra-
vir (n = 17). The majority of patients (99%) had suppressed HIV
RNA and the median CD4 cell count was 630 cells/mm3. Similar
to responses previously observed in HIV-uninfected patients,
the SVR rate with this regimen was 80% [42,93]. Although 20%
of patients stopped HCV treatment due adverse events, the safety
and tolerability proﬁle was consistent with prior studies.
Simeprevir plus peginterferon/ribavirin
Simeprevir plus peginterferon/ribavirin has been evaluated in
HIV-infected and uninfected patients with HCV genotype 1 coin-
fection. In the QUEST-1 and QUEST-2 studies, treatment-naïve,
HIV uninfected patients were randomized to simeprevir 150 mg
daily or placebo for 12 weeks plus peginterferon/ribavirin for
24 or 48 weeks response-guided therapy; the SVR rate was 80%
in simeprevir-treated patients and 50% in placebo-treated
patients [46,47]. Study C212 evaluated the same simeprevir-
based regimen in 106 HIV-infected patients with genotype 1
coinfection [39]. Treatment-naïve patients without cirrhosis
(n = 50) and those who had relapsed after prior peginterferon/
ribavirin therapy (n = 14) had response-guided therapy whereas
patients who had partial or null response during prior peginter-
feron/ribavirin therapy (n = 38) and those with cirrhosis (n = 4)
were treated for 48 weeks. Based on drug interaction studies in
healthy volunteers, HIV protease inhibitors were not permitted;
enrolled patients received rilpivirine, raltegravir, maraviroc,
enfuvirtide or were not taking antiretroviral. The majority ofJournal of Hepatology 2014patients were male (85%) and infected with HCV genotype 1a
(82%). Similar to the ﬁndings in HIV-uninfected patients, the
overall SVR rate was 74%; most treatment-naïve patients were
treated for 24 weeks and had higher SVR rates (79%) than
patients with prior null response, treated for 48 weeks (57%).
The safety and tolerability proﬁle was similar to that observed
in HIV-uninfected patients; rash/photosensitivity was reported
in 16 patients during the simeprevir phase of the study. Four
patients discontinued HCV treatment due to adverse effects.
Sofosbuvir plus peginterferon/ribavirin
In the NEUTRINO study, treatment-naïve, HIV-uninfected
patients with genotype 1, 4, 5 or 6 infection, who received sof-
osbuvir 400 mg daily plus peginterferon/ribavirin for 12 weeks
achieved a SVR rate of 90% and, in patients with genotype 1 infec-
tion, the SVR rate was 89% [62]. Rodriguez-Torres and co-workers
conducted a similar study of 12 weeks of treatment with sofosbu-
vir plus peginterferon/ribavirin in 23 HIV-infected patients with
genotype 1 (n = 19), 2 (n = 1), 3 (n = 2), and 4 (n = 1) coinfection
[38]. Based on the absence of drug interactions in healthy volun-
teers, patients received antiretroviral regimens containing
darunavir/ritonavir, raltegravir, efavirenz or rilpivirine. The
majority of patients were male (78%) and had high CD4 cell
counts (mean 563 cells/mm3). Similar to the ﬁndings in HIV-
uninfected patients, the overall SVR rate was 91% and, in patients
with genotype 1 infection, the SVR rate was 89%. Two patients
stopped HCV treatment due to of adverse events (anaemia and
altered mood); no serious adverse events were reported. Overall,
the safety and tolerability proﬁles were similar to that observed
in the study of HIV-uninfected patients.
Sofosbuvir plus ribavirin
In the SPARE study, sixty HIV-uninfected patients with HCV
genotype 1 infection were treated with sofosbuvir 400 mg daily
plus weight-based or low dose ribavirin for 24 weeks. Among
patients treated with weight-based ribavirin, Osinusi and
co-workers reported that 68% achieved SVR whereas lower SVR
rates were observed with low dose ribavirin [42]. Similarly, in
the FISSION study, HIV-uninfected persons with HCV genotype
2 and 3 infection were treated with sofosbuvir plus ribavirin for
12 weeks leading to SVR in 97% of patients with genotype 2 infec-
tion and in 56% of those with genotype 3 infection [21]. In the
VALENCE study, HIV-uninfected persons with HCV genotype 3
infection were treated with sofosbuvir plus weight-based ribavi-
rin for 24 weeks, leading to SVR in 85% of treatment-naïve and
treatment experienced patients [94].
In the PHOTON-1 study, the same regimen sofosbuvir and
weight-based ribavirin was evaluated in 223 HIV-infected
patients with genotype 1, 2 or 3 infections [35]. The treatment
duration was 24 weeks for treatment-naïve patients with geno-
type 1 (n = 114) and for, treatment-experienced patients with
HCV genotype 2 (n = 24) or 3 (n = 17). Sixty-eight treatment-naive
patients with HCV genotype 2 (n = 26) or 3 (n = 41) were treated
for 12 weeks. Based on the lack of relevant drug interactions in
healthy volunteer studies, patients received antiretroviral therapy
containing efavirenz, atazanavir/ritonavir, darunavir/ritonavir,
raltegravir and rilpivirine. The majority of patients enrolled were
male (81%–91%) and taking antiretroviral therapy (90%–98%); the
median CD4 cell count was high (585–658 cells/mm3) and fewvol. 61 j S108–S119 S113
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patients had cirrhosis (4%–24%). Among treatment-naïve patients,
the SVR rates varied by genotype and were similar to the SVR
observed in HIV-uninfected patients: genotype 1, 76%; genotype
2; 92%; genotype 3, 67%. Among treatment-experienced patients,
the SVR rate was 92% for patients with genotype 2 and 88% for
patients with genotype 3. The majority of virologic failures were
patients with on-treatment response followed by viral relapse
after stopping treatment; resistance to sofosbuvir was not
reported in patients with virologic failure. Treatment discontinu-
ation due to adverse effects was observed in 3% of patients treated
for 24 weeks; the most commonly reported adverse events were
fatigue, insomnia and headache. No adverse impact on HIV dis-
ease or its treatment with antiretroviral therapy was detected.
However, hyperbilirubinemia was seen in two-thirds of patients
taking atazanavir/ritonavir due to ribavirin-induced haemolysis,
coupled with atazanavir-induced inhibition of human UDP-glucu-
ronosyltransferase 1A (UGT1A). While this was not associated
with clinical harm, four patients switched from atazanavir to dar-
unavir. Anaemia (haemoglobin <10 grams/dl) occurred in 17% of
patients treated for 24 weeks; no patients took epoetin alfa or
had blood transfusions. Taken together, the ﬁndings of the clinical
trials of sofosbuvir/ribavirin found similar rates of sustained viro-
logic response in HCV genotype 1, 2, and 3 infected persons with
and with HIV coinfection (Fig. 1).
Sofosbuvir plus ledipasvir
The ﬁxed-dose combination of sofosbuvir/ledipasvir (one tablet
daily) has been studied with and without ribavirin in HIV-unin-
fected persons with genotype 1 infection. In the ION-1 and
ION-3 studies, treatment-naïve, HIV-uninfected patients were
treated with sofosbuvir/ledipasvir with or without ribavirin for
8, 12 or 24 weeks [53,55]. Among patients treated with sofosbu-
vir/ledipasvir (no ribavirin), the SVR rates were: 8 weeks, 94%
(ION-3); 12 weeks, 97% (ION-1 and ION-3); 24 weeks, 98% (ION-
1). Among patients treated with sofosbuvir/ledipasvir plus ribavi-
rin, the SVR rates were: 8 weeks, 93% (ION-3); 12 weeks, 97%
(ION-1); 24 weeks, 98% (ION-1). In the ION-2 study, which
enrolled HIV-uninfected patients with genotype 1 infection who
had failed prior peginterferon/ribavirin with or without telaprevir
or boceprevir, similar high SVR rates of 94% to 99% were observed
with 12 or 24 weeks of sofosbuvir/ledipasvir with or without
ribavirin [54].Genotype 1
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Fig. 1. Sustained virologic response rates observed with sofosbuvir/ribavirin
therapy in HIV-infected and uninfected persons with HCV genotype 1 or 2 or 3
infection (data derived from three separate studies: Fission, Valence and
Photon-1) [62,94,105].
S114 Journal of Hepatology 2014Based on these studies in HIV-uninfected patients, 12 weeks
of treatment with the ﬁxed-dose combination of sofosbuvir/ledi-
pasvir (no ribavirin) is under investigation in HIV-infected
patients with genotype 1 or 4 infection. The ION-4 study, a phase
3, multicentre trial to evaluate 12 weeks of treatment with the
ﬁxed-dose combination of sofosbuvir/ledipasvir one tablet daily
in HIV-infected persons coinfected with genotype 1 or 4, is
underway (ClinicalTrials.gov Identiﬁer: NCT02073656). In addi-
tion, sofosbuvir/ledipasvir will be evaluated for 24 weeks by the
French National Institute for Health and Medical Research and
the French National Agency for Research on AIDS and Viral Hep-
atitis (Inserm-ANRS) in HIV-infected patients who failed prior
telaprevir or boceprevir plus peginterferon/ribavirin therapy
(ClinicalTrials.gov Identiﬁer: NCT02125500).
While these studies are underway, preliminary data on the
safety, tolerability and efﬁcacy of the ﬁxed-dose combination of
sofosbuvir/ledipasvir have been presented by researchers at the
US National Institute of Health (NIH). In the ERADICATE study,
Osinusi and colleagues evaluated 12 weeks of sofosbuvir/ledipas-
vir in 50 treatment-naïve, HIV-infected patients with genotype 1
coinfection [36]. Enrolled patients were either not being treated
for HIV infection (CD4 >500 cells/mm3) or had suppressed HIV
RNA on antiretroviral therapy, containing tenofovir/emtricitabine
plus efavirenz, raltegravir, or rilpivirine. The majority of patients
was African-American (54%–81%) and infected with genotype 1a
(75%–81%). The median CD4 cell count was high in patients with
(n = 37; 576 cells/mm3) or without (n = 13; 687 cell/mm3) anti-
retroviral therapy. While ﬁnal efﬁcacy data have not been
reported, HCV RNA suppression during treatment with sofosbu-
vir/ledipasvir was observed in all patients (100%) and, among
the 34 patients who have been monitored for at least 4 weeks
after stopping treatment, viral relapse has not been observed.
The safety and tolerability proﬁle of sofosbuvir/ledipasvir for
12 weeks was similar to that observed in HIV-uninfected patients;
no patient discontinued treatment due to an adverse event; no
serious adverse events were reported. While additional drug
interaction studies are ongoing, three studies in healthy volun-
teers have assessed the interaction between the combination of
sofosbuvir/ledipasvir and the combination of antiretroviral regi-
mens including tenofovir/emtricitabine plus raltegravir, efavirenz
or rilpivirine. Sofosbuvir/ledipasvir did not affect levels of efavi-
renz, rilpivirine, or emtricitabine; however, tenofovir exposure
increased1.8 to 2.6-foldwith efavirenz and1.3 to 1.9-foldwith
rilpivirine [95]. Because this magnitude of increase in tenofovir
concentration is similar to that observed with HIV protease inhib-
itors, no dose adjustment of either treatment was recommended.
Sofosbuvir plus daclatasvir
In 211 HIV-uninfected patients with genotype 1, 2 or 3 infection,
sofosbuvir plus daclatasvir 60 mg daily with or without ribavirin
for 12 or 24 weeks led to a SVR in 98% of treatment-naïve
(n = 126) and treatment-experienced (n = 41) patients with
genotype 1, 92% of patients with genotype 2 (n = 26), and 89% of
patients with genotype 3 (n = 18) [12]. In HIV-infected patients,
the ALLY-2 study is underway to evaluate sofosbuvir plus dacla-
tasvir for 8 or 12 weeks in HIV-infected patients with genotype
1, 2, 3, 4, 5 or 6 coinfection (ClinicalTrials.gov Identiﬁer:
NCT02032888). Drug interaction studies in healthy volunteers
have been completed for daclatasvir and atazanavir/ritonavir,
efavirenz and tenofovir. No relevant interactions betweenvol. 61 j S108–S119
Table 2. Antiretroviral drug interactions for HCV treatment that include approved or available direct-acting antivirals.
Drug Notable antiretroviral drug-drug 
interactions 
Acceptable antiretroviral 
PegIFNα [105, 106] • None All with the exception of: 
• Zidovudine due to additive bone marrow suppression and clinical 
worsening of pancytopenia
Ribavirin [107, 108] • Didanosine All with the exception of:
• Zidovudine due to additive bone marrow suppression and worsening of 
anemia
• Didanosine due to increased exposure the active metabolite of 
didanosine leading to lactic acidosis, hepatomegaly/steatosis, and 
pancreatitis
Note: Increased indirect hyperbilirubinemia may occur due to interaction of 
ribavirin induced hemolysis and atazanavir-induced inhibition of UGTA1A
NS5B polymerase inhibitors
Sofosbuvir [109] • Tipranavir All with the exception of:
• Tipranavir due to the potential for decreased sofosbuvir exposure as a 
result of intestinal PgP induction
NS3 protease inhibitors 
Boceprevir [110] • Darunavir/ritonavir and other HIV-1 
protease inhibitors with or without 
ritonavir 
• Efavirenz
• Cobicistat anticipated to have 
interactions similar to ritonavir 
(elvitegravir/cobicistat)
Data support the use of boceprevir in combination with:
• Raltegravir or dolutegravir
• Rilpivirine
• Maraviroc - reduce dose to 150 mg twice daily
• Nucleos(t)ide reverse transcriptase inhibitors (NRTIs) including tenofovir, 
abacavir, emtricitabine, and lamivudine
• Limited data support co-administration with atazanavir/ritonavir or with 
etravirine 
Simeprevir [111] • Darunavir/ritonavir and other HIV-1 
protease inhibitors with or without 
ritonavir 
• Efavirenz
• Cobicistat anticipated to have 
interactions similar to ritonavir 
(elvitegravir/cobicistat)
Data support the use of simeprevir in combination with:
• Raltegravir (no data available for dolutegravir)
• Maraviroc
• Rilpivirine
• Nucleos(t)ide reverse transcriptase inhibitors (NRTIs) including tenofovir, 
abacavir, emtricitabine, and lamivudine 
Telaprevir [98, 112] • Darunavir or lopinavir or 
fosamprenavir with or without 
ritonavir
Data support the use of telaprevir in combination with:
• Atazanavir/ritonavir
• Raltegravir or dolutegravir or elvitegravir/cobicistat/tenofovir/emtricitabine
• Rilpivirine or etravirine or efavirenz (increase telaprevir dose to 1125 mg 
every 8 hours with efavirenz 
• Maraviroc – reduce dose to 150 mg twice daily
• Nucleos(t)ide reverse transcriptase inhibitors (NRTIs) including tenofovir, 
abacavir, emtricitabine, and lamivudine
NS5A inhibitors 
Daclatasvir [96] • None reported to date but 
published data has been limited.
Data support the use of daclatasvir in combination with:
• Atazanavir/ritonavir with daclatasvir dose reduction to 30 mg once daily 
• Efavirenz with daclatasvir dose increase to 90 mg once daily
• Tenofovir – no clinically relevant interactions observed 
Non-specific agents
PegIFN, peginterferon.
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JOURNAL OF HEPATOLOGYdaclatasvir and tenofovir were reported whereas daclatasvir
exposures were higher with atazanavir/ritonavir and lower with
efavirenz co-administration. Based on modelling, the researchers
recommended daclatasvir dose adjustment to 30 mg daily with
atazanavir/ritonavir and 90 mg once daily with efavirenz; this
strategy was incorporated in the ongoing trials [96].
ABT450/ritonavir/ombitasvir plus dasabuvir
In HIV-uninfected patients with genotype 1 infection, the combi-
nation of ABT-450/ritonavir (protease inhibitor)/ombitasvirJournal of Hepatology 2014(NS5A inhibitor) plus dasabuvir (non-nucleoside polymerase
inhibitor) has been evaluated with and without ribavirin in multi-
ple phase 3 studies. Among patients without cirrhosis, 12 weeks
of treatment with the three drugs plus ribavirin led to SVR in
96% of previously untreated patients (SAPPHIRE-I) and 96% of
prior peginterferon/ribavirin treated patients (SAPHIRE-II)
[57,58]. In the TURQUISE-II study, HIV-uninfected patients with
genotype 1 infection and compensated cirrhosis were treated for
12 or 24 weeks with the three drugs plus ribavirin cirrhotic;
SVR was achieved in 92% of cirrhotic patients treated for 12 weeks
and in 96% of those treated for 24 weeks [59]. The role of ribavirinvol. 61 j S108–S119 S115
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in this regimen was assessed in the PEARL III and IV studies [60].
HIV-uninfected patients with genotype 1a and 1bwere treated for
12 weeks with the three drugs plus placebo or ribavirin. In the
PEARL-III study, treatment-naïve patients with HCV genotype 1b
infection had a SVR rate of 99% with and without ribavirin. How-
ever, in the PEARL-IV study, treatment-naïve patients with HCV
genotype 1a infection had a SVR rate of 97% with ribavirin and
90% without ribavirin; this difference was largely due to more
virologic failure without ribavirin (7.8% compared to 2%).
Among HIV-infected patients with genotype 1 coinfection, the
TURQUOISE-I study is underway to evaluate the safety and efﬁ-
cacy of the combination of ABT-450/ritonavir/ombitasvir plus
dasabuvir plus ribavirin for 12 or 24 weeks duration (ClinicalTri-
als.gov Identiﬁer: NCT01939197); data from this clinical trial is
not yet available at this time. Drug interaction studies with the
combination of ABT-450/ritonavir/ombitasvir plus dasabuvir
and other drugs, including antiretrovirals, are underway.
MK-5172 plus MK8742
In HIV-infected and uninfected patients with genotype 1 infec-
tion, the once daily oral, two drug combination of MK-5172 (pro-
tease) plus MK-8742 (NS5A inhibitor) has been evaluated in a
phase 2b study, C-WORTHY (ClinicalTrials.gov Identiﬁer:
NCT01717326). Interestingly, patients with andwithout HIV were
enrolled under the same study protocol, underscoring the concept
that these populations respond similarly to HCV treatment with
DAAs. Recently reported results from the C-WORTHY study
appear to support this hypothesis [37,97]. In one part of the study,
treatment-naïve, non-cirrhotic, HIV-uninfected patients with
genotype 1 infection were treated with 12 weeks of the combina-
tion of MK-5172 plus MK-8472 with or without ribavirin; the SVR
rate was 94% in patients treated without ribavirin and 98% in
those treated with ribavirin. In a second part of the study, treat-
ment-naïve, non-cirrhotic, HIV infected patients (n = 59) were
treated with same regimen. The majority were male (80%) and
had infection with HCV genotype 1a (75%). Due to drug interac-
tions with other antiretroviral regimens, patients were required
to take raltegravir plus tenofovir or abacavir plus emtricitabine
or lamivudine. Preliminary HCV response data have been
reported. In the ribavirin-free arm (n = 30), one patient was lost
to follow-up and two had HCV breakthrough; the SVR rate
4 weeks after stopping therapy was 90%. In the ribavirin-contain-
ing arm (n = 29), no HCV breakthroughwas observed during treat-
ment and one patient had a viral relapse after stopping therapy;
the SVR rate 4 weeks after stopping the therapy was 97%. No
adverse effect was detected on HIV disease or its treatment with
antiretrovirals. Drug interaction studies with the combination of
MK-5172 plus MK-8742 and antiretroviral drugs are ongoing. In
addition, the phase 3, C-EDGE coinfection trial is underway and
will evaluate the ﬁxed-dose combination of MK-5172/MK-8742
(no ribavirin) for 12 weeks in HIV-infected patients with genotype
1, 4, 5, or 6 infection; patients are not permitted to receive the
ritonavir boosted or unboosted HIV protease inhibitor, efavirenz
or etravirine (ClinicalTrials.gov Identiﬁer: NCT02105662).Challenges to the use of direct-acting antivirals in HIV-infected
patients
Although still preliminary, the available data indicate that the
safety, tolerability and efﬁcacy of interferon-containing andS116 Journal of Hepatology 2014interferon-sparing DAA regimens will be similar in HIV-infected
and uninfected patients. If this is conﬁrmed in larger studies, only
unique aspects for the management of HCV infection in persons
with HIV coinfection may be needed to carefully consider the
potential for drug interactions between the patient’s antiretrovi-
ral drugs and the HCV direct-acting antiviral drugs (Table 2)
[98–100]. For some patients’ drug regimens, this may represent
the combination of many unique antiviral drugs each with a
different mechanism of action to inhibit HIV or HCV or to block
antiviral drug metabolism through inhibition of the patient’s
cytochrome P450 pathways (e.g., ritonavir or cobicistat)
[101,102]. As such, full understanding of possible drug interac-
tions between HIV and HCV drug regimens will be required
before these regimens can be safely combined. The expectation
is due to irreconcilable drug interactions with some antiviral
combinations. Not all antiretroviral regimens will be able to be
safely combined with all HCV direct-acting antiviral regimens;
as such, clinicians who treat patients with HIV/HCV coinfection
will need to carefully select the most appropriate HIV and HCV
treatment regimens for each patient on an individual basis. How-
ever, this challenge is mitigated by the ﬁnite and brief (12 weeks)
nature of HCV treatment, leading to cure in most patients
[103,104]. Thus, despite the potential for drug interactions
between HCV direct acting antivirals and antiretroviral, most
HIV/HCV coinfected patients will be able to beneﬁt from these
emerging therapies.Conclusion
Due to shared routes of transmission, acute and chronic coinfec-
tion with HCV is common among persons living with HIV infec-
tion in many regions [1,2]. In the era of effective antiretroviral
therapy, persons with acute HCV infection, particularly men
who have sex with men, are increasingly detected and persons
with chronic HCV infection, particularly older adults, are increas-
ingly developing life-threatening complications of HCV disease
including hepatocellular carcinoma and end-stage liver disease.
Over the past decade, the foundation of strategies for themanage-
ment of HIV-infected patient with acute or chronic HCV infection
has been treatment with peginterferon alfa. The effectiveness of
HCV treatment with peginterferon/ribavirin has been substan-
tially limited by the high burden of treatment-related side effects
and relatively low likelihood of HCV cure for many coinfected
patients. The emergence of multiple direct-acting antiviral drugs
and the regulatory approval of safe, tolerable and highly effective
interferon-free HCV treatments will dramatically change the
approach to HCV infection in HIV-infected persons. Preliminary
data from studies of interferon-free, oral combinations of DAAs
in HIV/HCV coinfected patients have been promising, supporting
the hypothesis that coinfection with HIV will not impair HCV cure
with these regimens. In the coming era of high effective HCV
treatment, the only special feature of management of coinfected
patients may be drug interactions between antiretrovirals and
DAAs. As such, a complete understanding of the pharmacokinetics
of antiviral drug regimens will be essential for the treatment of
HCV in patients with HIV coinfection.Financial support
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